FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2055761773> ?p ?o ?g. }

• W2055761773 endingPage "e57" @default.
• W2055761773 startingPage "e57" @default.
• W2055761773 abstract "Background Breast cancer of different molecular subtypes has different biological behaviour, patterns of failure, and outcome. The aim of the present study is to compare and contrast triple-negative breast cancer with triple-positive breast cancer. Methods Clinicopathological data from 60 breast cancer patients who received post-operative adjuvant radiation therapy in the Department of Radiation Oncology, Christian Medical College & Hospital from 2000 to 2012 and in whom immunohistochemistry for oestrogen receptor (ER), progesterone receptor (PR), and HER2 receptor status was available were identified. ER, PR, and HER2 expression determined by immunohistochemistry were used to construct the following subtypes: ER + or PR + and HER2+, ER−, PR−, and HER2−. The clinical characteristics, pathological features, natural history, and recurrence pattern of 30 patients with triple-negative breast cancer was compared with 30 patients with triple-positive disease. Actuarial rates were calculated using the Kaplan–Meier method and compared using the log-rank test. Cox proportional hazards models were used for multivariate analysis (MVA). Findings Of the 60 patients, 60% were aged ⩽ 50 years in both the molecular subtypes. The median age at presentation was 50 years. Triple-negative disease affected premenopausal women slightly more than women with post-menopausal status, by contrast, in the triple-positive molecular subtype, of whom 53% were post-menopausal. Most of the tumours involved the upper outer quadrant (43% versus 46%). Women presenting with T3 and T4 tumours accounted for 46% versus 66% of triple-positive and triple-negative patients, respectively. Axillary node positivity was noted in approximately 80% of patients in both groups. Neoadjuvant chemotherapy was offered to eight patients (26%) with triple-positive disease as opposed to 13 patients (43%) with triple-negative disease. All patients with the triple-positive subtype received hormonal therapy and only three patients received treatment with trastuzumab. Patients with metastatic disease at presentation were similar in both subtypes. None of the patients with the triple-positive molecular subtype presented with local recurrence while four patients in the triple negative subtype presented with it. On follow-up, metastatic disease was seen in four patients (13%) with the triple-positive subtype by contrast with 12 patients (40%) with triple-negative disease. Disease-free survival ranged from 7 to 48 months versus 11 to 40 months in both subtypes, respectively. Interpretation Patients with triple-positive breast cancer fair better than those with triple-negative disease. Our study suggests that patients with triple-negative breast cancer may benefit from novel strategies to improve locoregional control and distant metastatic disease. Breast cancer of different molecular subtypes has different biological behaviour, patterns of failure, and outcome. The aim of the present study is to compare and contrast triple-negative breast cancer with triple-positive breast cancer. Clinicopathological data from 60 breast cancer patients who received post-operative adjuvant radiation therapy in the Department of Radiation Oncology, Christian Medical College & Hospital from 2000 to 2012 and in whom immunohistochemistry for oestrogen receptor (ER), progesterone receptor (PR), and HER2 receptor status was available were identified. ER, PR, and HER2 expression determined by immunohistochemistry were used to construct the following subtypes: ER + or PR + and HER2+, ER−, PR−, and HER2−. The clinical characteristics, pathological features, natural history, and recurrence pattern of 30 patients with triple-negative breast cancer was compared with 30 patients with triple-positive disease. Actuarial rates were calculated using the Kaplan–Meier method and compared using the log-rank test. Cox proportional hazards models were used for multivariate analysis (MVA). Of the 60 patients, 60% were aged ⩽ 50 years in both the molecular subtypes. The median age at presentation was 50 years. Triple-negative disease affected premenopausal women slightly more than women with post-menopausal status, by contrast, in the triple-positive molecular subtype, of whom 53% were post-menopausal. Most of the tumours involved the upper outer quadrant (43% versus 46%). Women presenting with T3 and T4 tumours accounted for 46% versus 66% of triple-positive and triple-negative patients, respectively. Axillary node positivity was noted in approximately 80% of patients in both groups. Neoadjuvant chemotherapy was offered to eight patients (26%) with triple-positive disease as opposed to 13 patients (43%) with triple-negative disease. All patients with the triple-positive subtype received hormonal therapy and only three patients received treatment with trastuzumab. Patients with metastatic disease at presentation were similar in both subtypes. None of the patients with the triple-positive molecular subtype presented with local recurrence while four patients in the triple negative subtype presented with it. On follow-up, metastatic disease was seen in four patients (13%) with the triple-positive subtype by contrast with 12 patients (40%) with triple-negative disease. Disease-free survival ranged from 7 to 48 months versus 11 to 40 months in both subtypes, respectively. Patients with triple-positive breast cancer fair better than those with triple-negative disease. Our study suggests that patients with triple-negative breast cancer may benefit from novel strategies to improve locoregional control and distant metastatic disease." @default.
• W2055761773 created "2016-06-24" @default.
• W2055761773 creator A5014938370 @default.
• W2055761773 creator A5033086130 @default.
• W2055761773 creator A5042435115 @default.
• W2055761773 creator A5047745913 @default.
• W2055761773 creator A5057790304 @default.
• W2055761773 creator A5091821950 @default.
• W2055761773 date "2014-05-01" @default.
• W2055761773 modified "2023-10-11" @default.
• W2055761773 title "P0169 Molecular subtypes in breast cancer: Triple positive versus triple negative disease" @default.
• W2055761773 doi "https://doi.org/10.1016/j.ejca.2014.03.213" @default.
• W2055761773 hasPublicationYear "2014" @default.
• W2055761773 type Work @default.
• W2055761773 sameAs 2055761773 @default.
• W2055761773 citedByCount "0" @default.
• W2055761773 crossrefType "journal-article" @default.
• W2055761773 hasAuthorship W2055761773A5014938370 @default.
• W2055761773 hasAuthorship W2055761773A5033086130 @default.
• W2055761773 hasAuthorship W2055761773A5042435115 @default.
• W2055761773 hasAuthorship W2055761773A5047745913 @default.
• W2055761773 hasAuthorship W2055761773A5057790304 @default.
• W2055761773 hasAuthorship W2055761773A5091821950 @default.
• W2055761773 hasConcept C121608353 @default.
• W2055761773 hasConcept C126322002 @default.
• W2055761773 hasConcept C143998085 @default.
• W2055761773 hasConcept C204232928 @default.
• W2055761773 hasConcept C2780110267 @default.
• W2055761773 hasConcept C29456083 @default.
• W2055761773 hasConcept C50382708 @default.
• W2055761773 hasConcept C530470458 @default.
• W2055761773 hasConcept C71924100 @default.
• W2055761773 hasConcept C84606932 @default.
• W2055761773 hasConcept C98717036 @default.
• W2055761773 hasConceptScore W2055761773C121608353 @default.
• W2055761773 hasConceptScore W2055761773C126322002 @default.
• W2055761773 hasConceptScore W2055761773C143998085 @default.
• W2055761773 hasConceptScore W2055761773C204232928 @default.
• W2055761773 hasConceptScore W2055761773C2780110267 @default.
• W2055761773 hasConceptScore W2055761773C29456083 @default.
• W2055761773 hasConceptScore W2055761773C50382708 @default.
• W2055761773 hasConceptScore W2055761773C530470458 @default.
• W2055761773 hasConceptScore W2055761773C71924100 @default.
• W2055761773 hasConceptScore W2055761773C84606932 @default.
• W2055761773 hasConceptScore W2055761773C98717036 @default.
• W2055761773 hasLocation W20557617731 @default.
• W2055761773 hasOpenAccess W2055761773 @default.
• W2055761773 hasPrimaryLocation W20557617731 @default.
• W2055761773 hasRelatedWork W2047233110 @default.
• W2055761773 hasRelatedWork W2050936961 @default.
• W2055761773 hasRelatedWork W2375815296 @default.
• W2055761773 hasRelatedWork W2516201043 @default.
• W2055761773 hasRelatedWork W2584184160 @default.
• W2055761773 hasRelatedWork W2725964416 @default.
• W2055761773 hasRelatedWork W2765336906 @default.
• W2055761773 hasRelatedWork W2953241133 @default.
• W2055761773 hasRelatedWork W3198519606 @default.
• W2055761773 hasRelatedWork W4205578220 @default.
• W2055761773 hasVolume "50" @default.
• W2055761773 isParatext "false" @default.
• W2055761773 isRetracted "false" @default.
• W2055761773 magId "2055761773" @default.
• W2055761773 workType "article" @default.